

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Innovent

信達生物製藥

**INNOVENT BIOLOGICS, INC.**

*(Incorporated in the Cayman Islands with Limited Liability)*

**(Stock Code: 1801)**

## **INSIDE INFORMATION ANNOUNCEMENT UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2024**

This announcement is made by Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the first quarter of 2024, the Company achieved a total product revenue exceeding RMB1.7 billion, representing a robust year-over-year growth of over 60%. During the quarter, the Company fully leveraged the advantages of our commercial portfolio with broad indications and National Reimbursement Drug List (NRDL) coverage, coupled with extensive market access. The commercial portfolio continued its strong growth momentum, including strong sales performance of TYVYT® (sintilimab injection), robust growth of other products, as well as accelerated growth and increased contribution from new products.

The Company aims to build both oncology and general biomedicine (including cardiovascular and metabolism (CVM), autoimmune and ophthalmology) fields as key growth pillars for the Company's long-term development. As of now, the Company has ten approved products, three assets under the New Drug Application (NDA) review by the National Medical Products Administration (NMPA), five assets in Phase III or pivotal clinical trials, and 18 additional molecules in clinical studies. The Company believes that its robust innovative pipeline with broad market potential will provide a solid foundation for its long-term sustainable growth.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board  
**Innovent Biologics, Inc.**  
**Dr. De-Chao Michael Yu**  
*Chairman and Executive Director*

Hong Kong, China,  
April 30, 2024

*As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula and Dr. Shun Lu as Independent Non-executive Directors.*